11/11/2026
Last call to register! Join us for a live webinar exploring the emerging role of urine tumor DNA and RNA in urologic oncology.
What can urine-based molecular testing mean for the management of bladder and prostate cancer? Hear from two experts bringing complementary perspectives:
Dr. Guru Sonpavde, MD, Medical Director of Genitourinary (GU) Oncology at Adventhealth Cancer Institute will share the clinical perspective, covering:
● Unmet needs in bladder cancer management
● The evolving role of MRD in muscle-invasive bladder cancer
● Emerging applications in non-muscle-invasive disease
Dr. Min-Han Tan, Lucence's Founding CEO and Medical Director, will explore:
● The science behind urine tumor DNA and RNA detection
● Advances in next-generation sequencing (NGS)
● Emerging clinical evidence and applications around earlier detection of prostate cancer
Join us from wherever you are! We've scheduled the sessions to work across the US and Asia:
📍 US & Canada: Wednesday, 11 November
5:00 PM Pacific | 8:00 PM Eastern
📍 Singapore, Hong Kong, Manila & Kuala Lumpur: Thursday, 12 November
9:00 AM GMT+8
Don't miss this opportunity to hear the clinical and technology perspectives, and take part in the conversation.
Register now: https://lnkd.in/geRr_72J
hashtag hashtag hashtag hashtag hashtag